Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.03%
SPX
+0.44%
IXIC
+0.79%
FTSE
+0.29%
N225
-0.88%
AXJO
-1.82%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Recently from Cashu

publisher logo
Cashu

Travere Therapeutics Secures FDA Approval for Filspari, Advancing Nephrology Treatment

3 days ago
publisher logo
Cashu

FDA Approves Travere Therapeutics' Filspari for IgA Nephropathy Treatment, Enhancing Patient Care

5 days ago
publisher logo
Cashu

Travere Therapeutics Secures FDA Approval for Filspari in IgA Nephropathy Treatment

7 days ago

About

What does TVTX do?
Travere Therapeutics, based in San Diego, focuses on developing therapies for rare kidney and metabolic diseases, with products like FILSPARI for IgAN and Pegtibatinase for classical homocystinuria. Founded in 2003, the company employs 380 people and also offers Thiola for cystinuria.
Sector
💻 Health Care
IPO
CEO
Employees
385
Headquarters
California, USA
Website
http://www.retrophin.com

Key Stats

Market Cap
1.61B
Dividend Yield
0.00%
P/E Ratio
-9.53
EPS
-4.08
Revenue
233.18M
Avg. Volume
2.07M
Stocks
Health Care
tvtx
Travere Therapeutics
NASDAQ: TVTX
+0.64 (0.00%)
18.145
USD
At close at Sep 03, 13:26 UTC
Summary
News
Signals
Benchmarks
Financials